Skip to main content

Aktis Oncology, Inc.

AKTS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0002035832

In the last 90 days, Aktis Oncology, Inc. insiders filed 0 open-market purchases and 1 sale; 124 institutions reported holding it in 13F filings for Q3 2026, worth $716.6M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$901.1M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $258.6K in total
1
13F holdersQ3 2026, +15 vs. previous quarter
124
13F valueReported value at the end of Q3 2026
$716.6M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, Q3 FY2026
$3.90M
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
4.43M
Shares sold short
Change
+112.2K
+2.6% vs. previous
Days to cover
16.02
At average daily volume

Superinvestors holding AKTS, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding AKTS at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Aktis Oncology, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 24, 2026 (view filing)4:05 PM ETSep 231 dayCzibere AkosChief Medical OfficerSSale−12.5K$20.69−$258.6K−100.0%0 after2 lots10b5-1
Jul 21, 2026 (view filing)8:50 PM ETJul 201 dayHerrmann KenDirectorSSale−4.86K$24.56−$119.3K−100.0%0 after2 lots
Jul 20, 2026 (view filing)5:34 PM ETJul 173 daysHerrmann KenDirectorSSale−3.06K$25.21−$77.3K−100.0%0 after
Jul 10, 2026 (view filing)6:11 AM ETJul 82 daysRon-Bigger ShulamitChief Operating OfficerSSale−50.0K$27.75−$1.39M−100.0%0 after3 lots
Jul 10, 2026 (view filing)6:10 AM ETJul 82 daysCzibere AkosChief Medical OfficerSSale−50.0K$27.77−$1.39M−100.0%0 after3 lots
Jan 14, 2026 (view filing)6:19 PM ETJan 122 daysEvnin Luke and 7 others10% OwnerPPurchase+1.11M$18.00+$20.0M+12.2%10.3M afterDuplicate filing
Jan 14, 2026 (view filing)6:17 PM ETJan 122 daysGadicke Ansbert and 2 others10% OwnerPPurchase+1.11M$18.00+$20.0M+12.2%10.3M after
Jan 14, 2026 (view filing)Jan 122 daysFoley ToddDirector, 10% OwnerPPurchase+232.9K$18.00+$4.19M+5.8%4.24M after
Jan 12, 2026 (view filing)8:28 PM ETJan 12Same dayNodelman Oleg and 1 otherDirectorPPurchase+2.22M$18.00+$40.0MNew position347.3K after2 lots
Jan 12, 2026 (view filing)5:10 PM ETJan 12Same dayVida Ventures II, LLC and 1 other10% OwnerPPurchase+835.0K$18.00+$15.0MNew position157.4K after2 lotsDuplicate filing

Top 10 13F holders, Q3 2026

See all 124 holders

The largest institutional positions in Aktis Oncology, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding AKTS in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
MPM Oncology Impact Management LP4,835,872$94.2M7.25%00.0%Unchanged
EcoR1 Capital, LLC4,824,469$93.9M4.62%00.0%Unchanged
Blue Owl Capital Holdings LP3,343,827$65.1M11.92%+273,608+8.9%Added
T. Rowe Price Investment Management, Inc.3,333,026$64.9M0.05%+1,281,579+62.5%Added
BlackRock, Inc.2,780,745$54.1M0.00%+502,387+22.1%Added
RTW Investments, LP1,592,043$31.0M0.31%00.0%Unchanged
Wellington Management Group LLP1,471,969$28.7M0.01%−494,275−25.1%Reduced
Price T Rowe Associates Inc1,184,617$23.1M0.00%+421,118+55.2%Added
Vanguard Capital Management LLC1,180,925$23.0M0.00%+363,850+44.5%Added
Eventide Asset Management, LLC1,065,000$20.7M0.29%+558,000+110.1%Added

Holders of 5% or more of AKTS

See all 6 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Aktis Oncology, Inc..

Largest holders of AKTS from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
MPM Bioventures 2018, L.P.13D19.30%10.3M sharesNewJan 20, 20261 filingJan 20, 2026SEC
Eli Lilly & Co13D11.90%6.34M sharesNewJan 15, 20261 filingJan 15, 2026SEC
VV Manager II, LLC13D10.90%5.83M sharesNewJan 14, 20261 filingJan 14, 2026SEC
EcoR1 Capital, LLC13D9.10%4.86M sharesNewJan 20, 20261 filingJan 20, 2026SEC
T. Rowe Price Investment Management, Inc.13G6.20%3.33M sharesNewNov 16, 20261 filingNov 16, 2026SEC